Given the molecular differences of pRCC, their subtypes, and ccRCC, targeted agents such as tyrosine kinase inhibitors show significantly less efficacy in tumors with non-ccRCC including pRCC histology [28, 29]. This evidence concerns the gene PRCC and nonpapillary renal cell carcinoma.